VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME

Company Presented Entolimod™ from its TLR5 Platform to the Deputy Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs SAN ANTONIO, April 28, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a late-stage immunotherapeutics company, today announced that it briefed senior officials at the U.S. Department of War on Entolimod™ for acute radiation syndrome. The briefing, facilitated by American Defense International (ADI), was presented to the Deputy Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs and his team at the Pentagon.